WallStSmart

Innovex International, Inc (INVX)vsNOV Inc. (NOV)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

NOV Inc. generates 766% more annual revenue ($8.64B vs $997.53M). INVX leads profitability with a 6.2% profit margin vs 1.1%. INVX trades at a lower P/E of 33.5x. INVX earns a higher WallStSmart Score of 55/100 (C).

INVX

Buy

55

out of 100

Grade: C

Growth: 8.7Profit: 5.0Value: 6.3Quality: 8.5
Piotroski: 3/9Altman Z: 4.99

NOV

Buy

54

out of 100

Grade: C-

Growth: 4.7Profit: 5.0Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: 1.95
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

INVXUndervalued (+67.0%)

Margin of Safety

+67.0%

Fair Value

$77.11

Current Price

$29.08

$48.03 discount

UndervaluedFair: $77.11Overvalued

Intrinsic value data unavailable for NOV.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INVX4 strengths · Avg: 9.5/10
EPS GrowthGrowth
63.6%10/10

Earnings expanding 63.6% YoY

Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.9910/10

Safe zone — low bankruptcy risk

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

NOV2 strengths · Avg: 9.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

PEG RatioValuation
0.868/10

Growing faster than its price suggests

Areas to Watch

INVX4 concerns · Avg: 3.3/10
P/E RatioValuation
33.5x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
5.2%3/10

ROE of 5.2% — below average capital efficiency

Profit MarginProfitability
6.2%3/10

6.2% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

NOV4 concerns · Avg: 3.3/10
Altman Z-ScoreHealth
1.954/10

Grey zone — moderate risk

Return on EquityProfitability
1.5%3/10

ROE of 1.5% — below average capital efficiency

Profit MarginProfitability
1.1%3/10

1.1% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : INVX

The strongest argument for INVX centers on EPS Growth, Debt/Equity, Altman Z-Score.

Bull Case : NOV

The strongest argument for NOV centers on Price/Book, PEG Ratio. PEG of 0.86 suggests the stock is reasonably priced for its growth.

Bear Case : INVX

The primary concerns for INVX are P/E Ratio, Return on Equity, Profit Margin.

Bear Case : NOV

The primary concerns for NOV are Altman Z-Score, Return on Equity, Profit Margin. A P/E of 79.2x leaves little room for execution misses. Thin 1.1% margins leave little buffer for downturns.

Key Dynamics to Monitor

NOV carries more volatility with a beta of 0.94 — expect wider price swings.

INVX is growing revenue faster at 9.2% — sustainability is the question.

INVX generates stronger free cash flow (30M), providing more financial flexibility.

Monitor OIL & GAS EQUIPMENT & SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

INVX scores higher overall (55/100 vs 54/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Innovex International, Inc

ENERGY · OIL & GAS EQUIPMENT & SERVICES · USA

Innovex International, Inc. designs, manufactures, installs, rents, and sells a suite of well-centric engineered products to oil and gas industries globally. The company is headquartered in Humble, Texas.

NOV Inc.

ENERGY · OIL & GAS EQUIPMENT & SERVICES · USA

NOV Inc. is an American multinational corporation based in Houston, Texas. It is a leading worldwide provider of equipment and components used in oil and gas drilling and production operations, oilfield services, and supply chain integration services to the upstream oil and gas industry.

Visit Website →

Want to dig deeper into these stocks?